EFFICACY AND SAFETY OF GUSELKUMAB FOR CROHN’S DISEASE THROUGH 3 YEARS: GALAXI-1 LONG-TERM EXTENSION

Anita Afzali  ¹     Silvio Danese  ²     Remo Panaccione  ³     Brian G. Feagan  ⁴     David T. Rubin  ⁵     Bruce E. Sands  ⁶     Walter Reinisch  ⁷     Julian Panés  ⁸     Aparna Sahoo  ⁹     Natalie Terry  ⁹     Leonardo Salese  ⁹     Christopher Corbett  ¹⁰     Tadakazu Hisamatsu  ¹¹     Jane Andrews  ¹²     Geert R. D'Haens  ^13    
1 University of Cincinnati, Cincinnati, United States
² Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milan, Netherlands
³ University of Calgary, Calgary, Canada
⁴ The University of Western Ontario, London, Canada
⁵ University of Chicago Medicine, Chicago, United States
⁶ Icahn School of Medicine at Mount Sinai, New York, United States
⁷ Medical University of Vienna, Wien, Austria
⁸ Hospital Clínic Barcelona, Barcelona, Spain
⁹ Janssen, Spring House, United States
¹⁰ Janssen UK, Wycombe, United Kingdom
¹¹ Kyorin University, Tokyo, Japan
¹² Royal Adelaide Hospital, Adelaide, Australia
¹³ AMC Amsterdam Inflammatory Bowel Disease Centre - Academic Medical Center, AMC Amsterdam Inflammator, Amsterdam, Netherlands

Topic
Endoscopy, IBD

Session
IL-23-Blockers in IBD: Part 1

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)